Sparano 2010

1 Treatments

**Studied treatment** ixabepilone (40 mg/m\(^2\) intravenously on day 1) plus capecitabine (2,000 mg/m\(^2\) orally on days 1 through 14) given every 21 days

**Control treatment** capecitabine alone (2,500 mg/m\(^2\) on the same schedule) given every 21 days

**Concomittant treatments** -

2 Patients

**Patients** patients with metastatic breast cancer previously treated with anthracycline and taxanes

**Inclusion criteria** -

**Exclusion criteria** -

3 Methods

**Blinding** open

**Design** Parallel groups

**Centers** -

**Geographical area** -

**Sizes** -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>overall survival</td>
<td>-9</td>
<td>-9</td>
<td>0,90</td>
<td>[0,78; 1,03]</td>
</tr>
<tr>
<td>PFS</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>toxicity grade 3-4</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References